# A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency.

- **DOI:** [10.1007/s10875-025-01952-5](https://doi.org/10.1007/s10875-025-01952-5)
- **Rating:** Sound (3.4 out of 5)
- **Verdict:** A regulatory-grade PK bridge supports biweekly Xembify dosing and an enacted label expansion, but its fixed-sequence, homogeneous sample limits broader inference.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.1007%2Fs10875-025-01952-5

## Key claims

1. PK analyses showed that biweekly dosing of IGSC 20% was non-inferior to weekly dosing in treatment-experienced PI patients.
   - Support: Well-supported
   - Type: Primary finding
   - Basis: prespecified within-subject AUC comparison met the regulatory non-inferiority threshold with a lower 90% confidence bound above 0.80
   - Location: Abstract; Results, Pharmacokinetic Endpoints; Table 2
2. IGSC 20% showed qualitatively similar efficacy to previous studies.
   - Support: Tentative
   - Type: Secondary
   - Basis: infection outcomes were descriptive in a small study not designed or powered for efficacy
   - Location: Discussion, Overall paragraph
3. The IGSC loading/maintenance dosing regimen in naïve patients was safe and effective during the observation period.
   - Support: Tentative
   - Type: Secondary
   - Basis: the claim rests on six participants, dose adjustment in half, and descriptive safety and infection observations
   - Location: Abstract; Results, Pharmacokinetic, Efficacy, and Safety Endpoints

## Strengths

- **Primary endpoint directly answers regulatory question** The AUC comparison uses a prespecified lower 90% confidence-bound criterion of 0.80, and the observed ratio of 1.035 with a 90% CI of 1.0030–1.0685 meets that criterion.
  - Dimension: methodological rigour
  - Location: Methods, Objectives; Results, Pharmacokinetic Endpoints; Table 2
- **Regulatory pathway already produced label change** The Introduction states that biweekly administration was added to the US product label on the basis of this study, establishing a direct route from evidence to prescribing information.
  - Dimension: application pathway
  - Location: Introduction, paragraph 5
- **Efficacy uncertainty is explicitly carried forward** The Caveats paragraph states that the study was not designed or powered for efficacy and that those measures should not be considered conclusive. The conclusion accordingly describes efficacy only as qualitatively similar to previous studies.
  - Dimension: positioning
  - Location: Discussion, Caveats and Overall paragraphs

## Limitations

- **Fixed sequence leaves period effects unresolved** All treatment-experienced participants received weekly dosing before biweekly dosing, so regimen frequency is inseparable from treatment period. The Discussion does not address this design limitation.
  - Dimension: methodological rigour
  - Location: Methods, Study Design; Figure 1; Discussion, Caveats
- **Small homogeneous cohorts restrict generalization** The study treated 27 experienced and six naïve patients; all were Caucasian and nearly all had CVID. The naïve regimen and broader PI-population conclusions therefore rest on narrow evidence.
  - Dimension: application pathway
  - Location: Results, Patient Characteristics and Disposition; Table 1
- **Safety wording and oversight reporting need correction** The Abstract inconsistently calls severe events treatment-related and unrelated, while the Methods reports consent but no ethics-committee or IRB approval declaration. Detailed safety results clarify the event classification but not the oversight omission.
  - Dimension: reporting
  - Location: Abstract; Methods, Inclusion and Exclusion Criteria; Results, Safety Endpoints; Table 5

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The primary PK estimates are consistent across the Abstract, Results, and Table 2, but one Abstract safety sentence uses internally contradictory causality terminology. The detailed safety reporting indicates that severe TEAEs were unrelated and that suspected ADRs were mild or moderate.
- **Research conduct:** Noted. Written informed consent is specified, but the supplied multicentre clinical-study report does not declare ethics-committee or IRB approval. No conflict-of-interest disclosure is present in the supplied article.
- **Reference integrity:** Clean. 61 of 61 checkable references verified
  - 64 references in manuscript
  - 3 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Correction published 02 Feb 2026**, listed in Crossref: https://doi.org/10.1007/s10875-026-01983-6
- **Last checked:** 2026-10-17